- Home
- MNTK vs AUTL Comparison
MNTK vs AUTL Comparison
Compare MNTK & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNTK
- AUTL
- Stock Information
- Founded
- MNTK 1980
- AUTL 2014
- Country
- MNTK United States
- AUTL United Kingdom
- Employees
- MNTK N/A
- AUTL N/A
- Industry
- MNTK Natural Gas Distribution
- AUTL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MNTK Utilities
- AUTL Health Care
- Exchange
- MNTK Nasdaq
- AUTL Nasdaq
- Market Cap
- MNTK 339.0M
- AUTL 625.4M
- IPO Year
- MNTK 2021
- AUTL 2018
- Fundamental
- Price
- MNTK $2.13
- AUTL $2.63
- Analyst Decision
- MNTK Hold
- AUTL Strong Buy
- Analyst Count
- MNTK 3
- AUTL 5
- Target Price
- MNTK $3.33
- AUTL $9.32
- AVG Volume (30 Days)
- MNTK 215.6K
- AUTL 1.8M
- Earning Date
- MNTK 08-07-2025
- AUTL 08-07-2025
- Dividend Yield
- MNTK N/A
- AUTL N/A
- EPS Growth
- MNTK N/A
- AUTL N/A
- EPS
- MNTK 0.05
- AUTL N/A
- Revenue
- MNTK $179,552,000.00
- AUTL $9,011,000.00
- Revenue This Year
- MNTK $2.49
- AUTL $461.76
- Revenue Next Year
- MNTK $26.02
- AUTL $112.66
- P/E Ratio
- MNTK $41.66
- AUTL N/A
- Revenue Growth
- MNTK N/A
- AUTL N/A
- 52 Week Low
- MNTK $1.68
- AUTL $1.11
- 52 Week High
- MNTK $6.13
- AUTL $5.00
- Technical
- Relative Strength Index (RSI)
- MNTK 47.04
- AUTL 69.63
- Support Level
- MNTK $2.22
- AUTL $2.40
- Resistance Level
- MNTK $2.78
- AUTL $2.52
- Average True Range (ATR)
- MNTK 0.19
- AUTL 0.11
- MACD
- MNTK -0.02
- AUTL -0.00
- Stochastic Oscillator
- MNTK 27.38
- AUTL 85.97
About MNTK Montauk Renewables Inc.
Montauk Renewables Inc is a renewable energy company. It specializes in the recovery and processing of biogas from landfills and other non-fossil fuel sources for beneficial use as a replacement for fossil fuels. The firm develops, owns, and operates RNG projects that supply renewable fuel into the transportation and electrical power sectors. Montauk operates in two segments namely Renewable Natural Gas and Renewable Electricity Generation. It generates a majority of its revenue from the Renewable Natural Gas segment.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.